A grant from the Alzheimer’s Foundation of America will be used to purchase equipment to serve families affected by ...

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...

New research uncovers how declining protein clearance mechanisms with age lead to Alzheimer’s, Parkinson’s, and other ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Body composition emerges as a key factor in brain health, according to recent research. Targeted fat reduction and muscle building could be more effective than general weight loss in preventing ...

VERO BEACH — The Alzheimer’s Foundation of America has awarded a grant to the Alzheimer & Parkinson Association of Indian River County to expand its Project Lifesaver program, which provides ...

Yet despite decades of research, no treatment has been created that arrests Alzheimer’s cognitive deterioration, let alone ...

Image Credit: Kateryna Kon / Shutterstock Did you know that neurodegenerative diseases, including Alzheimer’s and Parkinson’s, primarily result from failures in clearing damaged proteins?

WEDNESDAY, Feb. 5, 2025 (HealthDay News) -- Hopes that GLP-1 drugs such as Ozempic and Wegovy could help slow Parkinson's ...

Prehospital hypoxia, hypotension, and hypocarbia each were associated with poor outcomes after traumatic brain injury, ...

A delay in getting to the rapid eye movement (REM) stage of sleep may be linked to Alzheimer's disease and related dementias, ...